Clinical Scorecard: Several Ophthalmic Products Are Voluntarily Recalled
At a Glance
| Category | Detail |
|---|---|
| Condition | Ophthalmic product safety |
| Key Mechanisms | Manufacturing cGMP deviations identified during FDA audit |
| Target Population | Consumers using affected ophthalmic products |
| Care Setting | Home and clinical settings |
Key Highlights
- Voluntary recall initiated by BRS Analytical Service, LLC
- Recall due to cGMP deviations identified by the FDA
- Health hazard to users is currently unknown
- Products may be of unacceptable quality
- Recall affects products shipped from May 26, 2023, to April 21, 2025
Guideline-Based Recommendations
Diagnosis
- Identify affected ophthalmic products based on recall notice
Management
- Cease use of recalled products immediately
Monitoring & Follow-up
- Monitor for any adverse effects in patients using recalled products
Risks
- Potential patient risks due to use of products with cGMP deviations
Patient & Prescribing Data
Patients using recalled ophthalmic products
Patients should discontinue use and consult healthcare providers
Clinical Best Practices
- Stay informed about product recalls and safety alerts
- Report any adverse effects from recalled products to healthcare authorities
- Educate patients on the importance of using FDA-compliant products
References
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.